| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $22,557,272 ) (Continued on the next page) |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA141244 | Allosteric Regulation of MDMX by Protein Disorder | 000 | 14 | NIH | 12/11/2024 | $304,497 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA258089 | Eco-evolutionary drivers of clonal dynamics during UV-induced skin carcinogenesis (PQ3) | 000 | 5 | NIH | 3/4/2025 | $576,018 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255265 | Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | 000 | 5 | NIH | 3/4/2025 | $488,935 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255265 | Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers | 001 | 5 | NIH | 6/11/2025 | $54,326 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA276496 | Body composition and adiposity-associated thromboinflammation in colorectal cancer prognosis | 000 | 2 | NIH | 3/20/2025 | $598,180 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA276496 | Body composition and adiposity-associated thromboinflammation in colorectal cancer prognosis | 001 | 2 | NIH | 6/12/2025 | $66,462 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 001 | 5 | NIH | 5/5/2025 | $0 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 002 | 5 | NIH | 5/22/2025 | $41,694 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 000 | 5 | NIH | 3/20/2025 | $375,244 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279713 | RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | 001 | 3 | NIH | 6/17/2025 | $46,111 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279713 | RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | 000 | 3 | NIH | 3/20/2025 | $414,990 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA288927 | Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | 001 | 2 | NIH | 5/22/2025 | $19,692 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA288927 | Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | 000 | 2 | NIH | 3/3/2025 | $177,242 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA280404 | Investigating lipid phenotype as a metabolic adaptation to microenvironmental stress | 000 | 2 | NIH | 2/14/2025 | $84,250 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 001 | 3 | NIH | 5/22/2025 | $52,200 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 000 | 3 | NIH | 2/14/2025 | $469,813 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 001 | 3 | NIH | 6/23/2025 | $53,438 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 3 | NIH | 11/15/2024 | $480,943 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 001 | 3 | NIH | 6/16/2025 | $59,638 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 3 | NIH | 12/18/2024 | $536,745 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P30CA076292 | Moffitt Cancer Center Support Grant | 001 | 27 | NIH | 3/5/2025 | $3,649,340 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 2 | NIH | 12/12/2024 | $541,074 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA292692 | Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | 000 | 2 | NIH | 6/26/2025 | $485,494 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 000 | 2 | NIH | 5/12/2025 | $553,041 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 2 | NIH | 11/14/2024 | $84,250 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 001 | 2 | NIH | 6/4/2025 | $63,562 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 2 | NIH | 1/14/2025 | $572,062 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 000 | 5 | NIH | 3/21/2025 | $370,575 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262483 | Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | 000 | 4 | NIH | 6/25/2025 | $485,968 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DA055298 | Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation | 000 | 4 | NIH | 5/16/2025 | $759,650 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255398 | Characterizing oncogenic function of ITCH in melanoma | 000 | 5 | NIH | 7/1/2025 | $357,913 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249016 | Radiomics and Pathomics to predict upstaging of DCIS | 000 | 5 | NIH | 4/25/2025 | $614,438 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA249016 | Radiomics and Pathomics to predict upstaging of DCIS | 001 | 5 | NIH | 5/22/2025 | $68,269 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM142577 | New reagents for C-C and C-N bond formation | 000 | 5 | NIH | 4/16/2025 | $411,750 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P01CA250984 | Identifying Metabolic Vulnerabilities in Lung Cancer | 000 | 5 | NIH | 6/25/2025 | $2,032,950 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 001 | 5 | NIH | 5/22/2025 | $44,459 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 5 | NIH | 2/13/2025 | $400,132 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 001 | 5 | NIH | 5/22/2025 | $47,602 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 000 | 5 | NIH | 3/13/2025 | $428,435 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262530 | Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | 000 | 5 | NIH | 6/26/2025 | $681,912 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 001 | 6 | NIH | 5/1/2025 | $498,468 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA253219 | Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults | 000 | 6 | NIH | 5/23/2025 | $319,019 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299480 | The MIND-BC Study: MIND diet for Breast cancer Cognition | 000 | 1 | NIH | 3/7/2025 | $713,235 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R34CA297368 | Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers | 000 | 1 | NIH | 4/1/2025 | $316,873 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 003 | 6 | NIH | 3/6/2025 | $3,083 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 003 | 6 | NIH | 3/6/2025 | $58,549 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 000 | 6 | NIH | 1/16/2025 | $463,375 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279023 | Epigenetic and metabolic bottlenecks of tumorigenesis | 000 | 2 | NIH | 6/13/2025 | $598,888 |
| | 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299899 | Structure-function studies of LAG3 interactions with antibodies and cellular ligands | 000 | 1 | NIH | 3/24/2025 | $549,962 |
|
